Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065316 | 0.84 | DHFR (0.32) | — | |
| SCHEMBL7066267 | 0.83 | DHFR (0.33) | — | |
| SCHEMBL7066181 | 0.80 | USP30 (0.36) | — | |
| SCHEMBL6791730 | 0.77 | NR1H2 (0.36) | CYP3A4LMNA | |
| SCHEMBL6328305 | 0.77 | NR1H2 (0.36) | CYP3A4LMNA | |
| SCHEMBL6327631 | 0.77 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL6330323 | 0.77 | CYP3A4 (0.33) | CYP3A4 | |
| Hydrochloric Acid SCHEMBL7066452 | 0.77 | CYP1A2 (0.38) | CYP11B2CYP11B1CYP1A2CYP3A4GABRA1 | |
| SCHEMBL7068838 | 0.77 | CYP1A2 (0.33) | CYP11B2CYP11B1CYP1A2CYP3A4GABRA1 | |
| SCHEMBL6324214 | 0.76 | CYP3A4 (0.34) | CYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6579886-B2 | Ionotropic glutamate receptors; 6-((4-carboxylic acid-1H-imidazol-1-yl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3 -carboxylic acid | ELI LILLY AND COMPANY | 2003-06-17 | — | — | US | disclosed |
| US-20030055081-A1 | Selective iglur5 receptor antagonists | ELI LILLY AND COMPANY | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055081-A1 | Selective iglur5 receptor antagonists | GRM5, GRIK5, GPR35 | CYP11B2 825/4885CYP11B1 1115/4885CYP1A2 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.